Besheer Joyce, Lepoutre Veronique, Hodge Clyde W
Bowles Center for Alcohol Studies, Department of Psychiatry, Thurston-Bowles Building, University of North Carolina at Chapel Hill, CB#7178, Chapel Hill, NC 27599, USA.
Psychopharmacology (Berl). 2004 Jul;174(3):358-66. doi: 10.1007/s00213-003-1769-3. Epub 2004 Feb 19.
A growing number of studies suggest that gamma-aminobutyric acid type-B (GABA(B)) receptor agonists reduce alcohol use and craving.
This study was designed to further clarify behavioral mechanism(s) by which GABA(B) agonists may decrease alcohol reinforcement.
Male C57BL/6 J mice were trained to lever press on a concurrent schedule of ethanol (10% v/v) and water reinforcement during 16-h overnight sessions. Effects of the GABA(B) agonist baclofen (0-17 mg/kg, IP) or SKF 97541 (0-1 mg/kg, IP) were examined on parameters of self-administration. Subsequently, potential motor inhibition and interaction with ethanol-induced sedation by GABA(B) agonists was examined in ethanol naive and self-administering mice.
Baclofen (10 mg/kg) and SKF 97541 (0.3 mg/kg) reduced ethanol-reinforced responding. In a locomotor activity test, these doses of the GABA(B) agonists inhibited locomotion in the ethanol-experienced mice and in a group of ethanol-inexperienced mice; locomotor suppression was greater in the ethanol-inexperienced mice. These doses of the GABA(B) agonists also potentiated the sedative effects of ethanol (4 g/kg) and converted a nonsedative dose of ethanol (2 g/kg) into a fully sedative dose. GABA(B) agonist enhancement of the sedative effects of ethanol was less pronounced in ethanol self-administering mice, suggesting cross-tolerance at the low dose of ethanol.
GABA(B) agonists decrease the reinforcing effects of ethanol at doses that inhibit locomotor activity and potentiate the sedative hypnotic effects of ethanol. These nonspecific effects of GABA(B) agonists were reduced in alcohol experienced mice, suggesting cross-tolerance to the inhibitory properties of GABA(B) positive modulation. These data question the safety of prescribing GABA(B) agonists to alcoholics since these drugs may potentiate ethanol's sedative/hypnotic effects during relapse.
越来越多的研究表明,γ-氨基丁酸B型(GABA(B))受体激动剂可减少酒精使用和渴望。
本研究旨在进一步阐明GABA(B)激动剂可能降低酒精强化作用的行为机制。
雄性C57BL/6 J小鼠在16小时的夜间训练中,按照乙醇(10% v/v)和水强化的并行程序进行杠杆按压训练。研究了GABA(B)激动剂巴氯芬(0 - 17毫克/千克,腹腔注射)或SKF 97541(0 - 1毫克/千克,腹腔注射)对自我给药参数的影响。随后,在未接触过乙醇和正在自我给药的小鼠中,研究了GABA(B)激动剂潜在的运动抑制作用以及与乙醇诱导的镇静作用的相互作用。
巴氯芬(10毫克/千克)和SKF 97541(0.3毫克/千克)减少了乙醇强化的反应。在运动活动测试中,这些剂量的GABA(B)激动剂抑制了接触过乙醇的小鼠以及一组未接触过乙醇的小鼠的运动;未接触过乙醇的小鼠运动抑制作用更强。这些剂量的GABA(B)激动剂还增强了乙醇(4克/千克)的镇静作用,并将非镇静剂量的乙醇(2克/千克)转变为完全镇静剂量。在自我给药的小鼠中,GABA(B)激动剂增强乙醇镇静作用的效果不太明显,表明在低剂量乙醇时存在交叉耐受性。
GABA(B)激动剂在抑制运动活动并增强乙醇镇静催眠作用的剂量下,可降低乙醇的强化作用。在接触过酒精的小鼠中,GABA(B)激动剂的这些非特异性作用有所减弱,表明对GABA(B)阳性调节的抑制特性存在交叉耐受性。这些数据对给酗酒者开GABA(B)激动剂的安全性提出了质疑,因为这些药物可能在复发期间增强乙醇的镇静/催眠作用。